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Abstract 
Panton Valentine Leukocidin (PVL) is a pore-forming toxin secreted by 
Staphylococcus aureus. PVL has gained enormous attention over the last few years, 
because clinical data revealed that the presence of this toxin was found associated 
with life-threatening cases of necrotizing pneumonia in young adults. Moreover, 
methicillin resistant S. aureus (MRSA) strains emerged in the community over the 
last years, most of which carrying the gene for PVL. Because these new bacterial 
strains have been shown to be far more virulent than hospital associated MRSA, we 
hypothesized that PVL might be an important virulence factor. 
The lab of Sylvia Knapp studied the role of PVL in lung inflammation and recently 
identified that CD14 and TLR2 are required for PVL to induce an inflammatory 
response both in vitro and in vivo. This inflammatory response was shown to be 
independent of PVL’s pore-forming properties and was induced by one subunit of 
PVL (called LukS-PV).  
Because PVL alone was not capable of inducing lung necrosis, we hypothesized that 
PVL might enhance the activity of other bacterial virulence factors, and that only the 
combined effect can trigger pulmonary necrosis. The topic of my diploma thesis was 
to investigate the potentially synergistic effects of PVL and other known 
staphylococcal virulence factors during lung inflammation. As such I studied the 
potential synergism between PVL and protein A, a well-known virulence factor of S. 
aureus. Protein A has been earlier shown to importantly contribute to S. aureus 
pneumonia as it is capable of inflaming the lung via involvement of TNF-R1. 
Based on experiments I performed we observed that PVL and protein A indeed 
synergize in causing lung inflammation both in vitro and in vivo. This synergistic 
effect depended on the presence of TLR2 (PVL receptor) and TNF-R1 (protein A 
receptor) in vitro. When studying this synergism during lung inflammation in mice, we 
unexpectedly discovered that PVL itself was almost incapable of inducing lung 
inflammation in the absence of TNF-R1 in vivo. Absence of TNF-R1 on macrophages 
did not prevent PVL from inducing an inflammatory response, hence ruling out the 
possibility that PVL triggers inflammation via TNF-R1 but rather suggesting that the in 
vivo phenotype was based on indirect effects of soluble TNF-!. In accordance, 
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microarray and PCR results confirmed that TNF-! is one of the strongest induced 
cytokines in response to PVL stimulation of macrophages. Because both 
macrophages and respiratory epithelial cells express TNF-R1 in vivo, we performed 
bone marrow transplant experiments to identify the respective contribution to PVL 
induced lung inflammation. While PVL-induced lung inflammation was present in 
WT/WT mice and abolished in KO/KO animals, both chimeric WT/KO and KO/WT 
groups showed an intermediate phenotype. These data suggest that TNF importantly 
contributes to PVL-induced lung inflammation and that TNF-R1 on macrophages and 
epithelial cells is required for this response. 
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Abstract auf Deutsch 
Panton Valentine Leukocidin (PVL) ist ein Poren-bildendes Toxin, das von 
Staphylococcus aureus produziert wird. PVL ist ein seit langem bekanntes Toxin, mit 
Großteils unbekanntem Wirkmechanismus und hat in den letzten Jahren besondere 
Aufmerksamkeit erregt. Klinische Studien belegen, dass dieses Toxin mit 
lebensbedrohlichen Fällen von nekrotisierender Pneumonie in jungen Erwachsenen 
assoziiert ist. Des Weiteren ist eine auffällige Assoziation mit Methicillin resistenten 
S. aureus Stämmen (MRSA) gegeben, die auch außerhalb von Krankenhäusern 
verbreitet werden. Da diese neuen Varianten von S. aureus eine wesentlich höhere 
Virulenz besitzen als nosokomiale Stämme, vermuten wir, dass PVL hierbei eine 
tragende Rolle spielt. 
 
Das Labor von Sylvia Knapp erforscht die Rolle von PVL in Entzündungsvorgängen 
der Lunge und entdeckte kürzlich, dass die Rezeptoren CD14 und TLR2 notwendig 
sind in der Initiation der Entzündungsreaktion in vitro als auch in vivo. Die Auslösung 
der Entzündung ist unabhängig der Fähigkeit von PVL, Poren in Zellmembranen zu 
bilden und wird von einer PVL Untereinheit ausgelöst, die lukS-PV genannt wird. 
 
Da PVL alleinig nicht in der Lage ist eine Nekrose der Lunge hervor zu rufen, 
vermuteten wir, dass PVL die Aktivität anderer bakterieller Virulenzfaktoren 
verstärken könnte, und diese zusammengefasst in der Lage sind eine Nekrose 
hervorzurufen. Das Thema meiner Diplomarbeit beschäftigte sich mit den möglichen 
synergistischen Effekten von PVL und anderen, bereits bekannten Virulenzfaktoren 
von S. aureus bei Entzündungen der Lunge. Dies umfasste auch Protein A, einen 
weiteren Virulenzfaktor von S. aureus, bzw. die potentielle Verstärkung der 
Entzündung durch diesen und PVL. Es ist bekannt, dass Protein A erheblich zur 
Entstehung von S. aureus vermittelter Lungenentzündung beiträgt, und alleine in der 
Lage ist eine Entzündungsreaktion in der Lunge durch Interaktion mit TNF-R1 
auszulösen.  
Basierend auf in vitro und in vivo Experimenten, die ich durchführte, konnten wir 
tatsächlich einen synergistischem Effekt von Protein A und PVL bei der Auslösung 
einer Entzündungsreaktion in der Lunge beobachten. Dieser Effekt war in einem in 
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vitro Experiment abhängig von der Präsenz von TLR2 (PVL Rezeptor) und TNF-R1 
(Protein A Rezeptor). Während der Untersuchung des synergistischen Effektes von 
PVL und Protein A entdeckten wir in einem in vivo Experiment  
überraschenderweise, dass die Entzündungsauslösung durch PVL bei Abwesenheit 
von TNF-R1 fast vollständig inhibiert wurde. Das Fehlen von TNF-R1 auf alveolären 
Makrophagen verhinderte nicht die PVL vermittelte Entzündungsreaktion was 
bedeutet, dass PVL keine Entzündungsreaktion direkt über TNF-R1 vermitteln kann. 
Wir vermuteten in unserem in vivo Modell allerdings einen wesentlich komplizierteren 
Mechanismus durch frei lösliches TNF-α, dessen Ausschüttung möglicherweise eine 
Folge der Präsenz von PVL sein könnte. In der Tat bestätigten weitere PCR und 
Microarray Experimente, dass TNF-α eines der durch PVL am stärksten induzierten 
Zytokine in alveolären Makrophagen ist. Da sowohl alveoläre Makrophagen, als auch 
Lungenepithelzellen in vivo TNF-R1 exprimieren, war es notwendig eine 
Knochenmarkstransplantation durch zu führen um die jeweilige Bedeutung in PVL 
induzierter Entzündungsreaktionen der Lunge aufzuklären. Während in WT/WT 
Mäusen PVL in der Lage war eine Entzündungsreaktion aus zu lösen war dies in 
KO/KO Mäusen nicht möglich. Beide chimären Genotypen (WT/KO & KO/WT) 
zeigten einen intermediären Phänotyp. Diese Daten deuten darauf hin, dass TNF-α 
wesentlich zur PVL-vermittelten Entzündungsreaktion beiträgt, und dass TNF-R1 auf 
alveolären Makrophagen als auch auf Epithelzellen  für diesen Effekt notwendig ist.  
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Introduction 
	  
Staphylococcus aureus 
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium and is part of the 
normal flora of the skin and the upper airway tract [1]. It has a circular chromosome 
of approx. 2800bp and can harbor prophages, plasmids and transposons, which 
facilitate genetic exchange with other Gram-positive bacteria. The cell wall of S. 
aureus consists of peptidoglycan (up to 50%), lipoproteins and teichoic acids, which 
are all recognized by different receptors of the innate immune system. Based on the 
microcapsule present in most staphylococci, 11 serotypes have been described, of 
which serotype 5 and 8 count responsible for most infections in humans [2]. The 
microcapsule can be considered a virulence factor as it has the ability to inhibit 
phagocytosis. S. aureus also developed other strategies to prevent innate immune 
responses. As such, staphylococcal surface proteins like protein A prevent 
phagocytosis. Protein A binds to the Fc part of human IgG, consecutively preventing 
opsonization and phagocytosis [3].  
S. aureus is responsible for a wide range of clinically important diseases, ranging 
from minor skin infections such as furunculosis, to life threatening diseases such as 
osteomyelitis, pneumonia, endocarditis, toxic shock syndrome and septicemia [4-9]. 
While osteomyelitis and endocarditis can occur in otherwise healthy people, 
pneumonia is mostly restricted to elderly patients with underlying disorders like 
cardiovascular and malignant diseases, chronic pulmonary diseases or diabetes 
mellitus [10]. All together, S. aureus is the single most important pathogen in causing 
infectious diseases in humans [5]. 
S. aureus harbors various toxins that contribute to its virulence and enhance 
progression as well as severity of diseases. The toxins of S. aureus can be 
categorized into three groups, namely 1) pore forming toxins, 2) exfoliative toxins, 
and 3) entero- & toxic shock syndrome toxins (TSST). Pore-forming toxins consist of 
hemolysins, the latter being further divided in α, β and γ hemolysins with different cell 
type specifity for their lysis capability [11]. Panton Valentine leukocidin (PVL) is part 
of the β hemolysin group, because of its beta- barrel- pore forming property and will 
be explained in more detail below [12]. Exfoliative toxins contain a protease activity 
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and can therefore cause blistering of the skin via cleavage of cadherins [13]. About 
20 subtypes of S. aureus enterotoxins have been discovered over the last years and 
some of them cause severe gastrointestinal afflictions, while all of them (including 
TSST) show superantigen properties, i.e. activation of T- cell proliferation by binding 
to MHC class II leading to massive cytokine release [14].  
 
Emerengence of MRSA & PVL positive strains in the community  
Methicillin resistant S. aureus (MRSA) is a consequence of antibiotic usage. MRSA 
were first described in the 1960ies, but continuous usage of antibiotics has led to 
constantly rising incidences of these strains over the last decades [15, 16]. Most 
MRSA isolates are confined to hospitals, and these strains are usually of low 
virulence and associated with nosocomial infections. Only recently, a number of new 
MRSA strains in the community have been discovered, and were named community-
associated (CA)-MRSA. Quite alarmingly, these CA-MRSA clones rapidly spread 
around the globe and epidemiological data indicate that CA-MRSA strains are far 
more virulent than their hospital-confined relatives [17, 18].  
Resistance to Methicillin is mediated by the acquisition of penicillin-binding protein 
(PBP2a) encoded by the mecA gene and is characterized by low affinity to β-lactam 
based antibiotics. While the four native peptidoglycan synthethases (penicillin- 
binding proteins 1 to 4) are inactivated by their high affinity to β-lactam antibiotics, the 
PBP2a is still able to perform cell wall synthesis in the presence of β-lactams [19]. 
Nosocomial MRSA isolates usually carry large staphylococcal chromosomal cassette 
mec (SCCmec) of I, II or III of sizes ranging from 34 to 67kb [20]. In contrast to 
nosocomial MRSA, CA-MRSA strains carry the smaller (21 to 36kb) SCCmec IV, V or 
VII [21]. It has been speculated that the smaller sizes of SCCmec types found in CA-
MRSA facilitate the acquisition by Methicillin sensitive S. aureus (MSSA) [22]. 
Adding to the danger of CA-MRSA, many of these strains carry genes for the pore-
forming toxin PVL [15]. Recent studies have shown that PVL positive S. aureus 
strains were related to hemorrhagic, necrotizing pneumonia in otherwise 
immunocompetent healthy children and young adults [23]. Of great clinical 
importance, high mortality rates of up to 75% were described in these patients [24]. 
Although PVL has been shown to be associated with these serious lung infections, 
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and also skin infections, the causal link has never been clearly demonstrated. A 
series of recent investigations provided both prove and doubt in the role of PVL as a 
critical factor for CA-MRSA-associated pneumonia [12, 25-32]. 
 
PVL is a beta barrel octamer pore-forming toxin comprised of two subunits (LukF-PV 
and LukS-PV) that was recently found to be associated with necrotizing pneumonia 
and skin infections in humans (Fig.1&2) [33, 34].  
 
Figure 1: Three dimensional structure of LukS-PV (left) and lukF-PV (right) [33]. 
 
 
Figure 2: (A) Side view and (B) top view of fully assembled PVL octamer. The octamer is comprised 
of lukS-PV and lukF-PV in a 1:1 stoichiometry [34]. 
 
The molecular mechanism as to how PVL is able to cause necrosis of cells and 
tissues is poorly understood and still contradictory [31]. Previously it was shown that 
high doses of PVL have the ability to kill neutrophils and low doses to mediate 
apoptosis of neutrophils [12, 35].  
PVL is integrated into the chromosome by a lysogenic bacteriophage (phiSLT) in a 
region distinct from SCCmec (Fig.3). The relatively small SCCmec IV & V cassettes 
seem to have no negative effect on the genetic fitness of S. aureus. The bigger 
SCCmec types I, II and III, which are carrying resistance genes for a wide range of 
antibiotics, seem to be not fit enough to survive within the community and are 
Page	  12	  
	  
	  
therefore only distributed in nosocomial S. aureus strains [15]. The increased 
presence of PVL has been attributed by some authors to the fact that PVL-positive 
bacteria are frequently found in necrotic skin lesions, which allows for easy spread 
via skin contact [36, 37]. 
 
 
  
Figure 3: Suggested model for the emergence of PVL producing CA-MRSA; A methicillin susceptible 
strain (MSSA) is infected and lysogenized by a phage (phiSLT) carrying lukS-PV and lukF-PV. 
Independently a SCCmec cassette of type IV or V is subsequently integrated into the chrosmosome 
by horizontal gene transfer [15]. 
 
Respiratory tract infections and pathogen encountering lung cells 
The lungs are exposed to a large array of air borne microbes and particles and hence 
are exceptionally sensitive to potential bacterial infections. While the upper 
respiratory tract is colonized by a large number of microorganisms that usually don’t 
cause any strong inflammatory response, the lower respiratory tract remains 
relatively ‘sterile’. Even though, it was recently shown that also the lower respiratory 
tract can host microorganisms [38]. With an incidence of more than 429 million cases 
of lower respiratory tract infections in 2004, respiratory tract infections are the 3rd 
leading cause of death worldwide [39]. The innate immune system provides the first 
line of defense against inhaled pathogens and particles and consists of cellular and 
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soluble factors. Soluble factors also include plasma components, which are 
translocated to the site of infection by pericellular and transcellular transport 
mechanisms via endothelial and epithelial cells and include natural antibodies, 
complement proteins, C-reactive protein and pentraxin 3. All of these factors support 
host defense via opsonization or their bacteriostatic and microbicidial properties [40-
42]. Alveolar macrophages and lung-epithelial cells, which are located at the air 
tissue interphase, are the first cells to encounter pathogens. Both above mentioned 
cells types express an array of pattern recognition receptors (PRR). Among those 
PRRs are Toll-like receptors (TLRs), scavenger receptors as well as cytosolic 
receptors like NOD like receptors (NLR’s), RIG-I like receptors (RLR’s) and recently 
found intracellular DNA and RNA sensing receptors [43, 44]. To attract other effector 
cells, macrophages and epithelial cells secrete an array of inflammatory mediators 
upon recognition of bacteria [43]. These inflammatory mediators (i.e. cytokines and 
chemokines) lead to the recruitment of PMNs and monocytes [45, 46]. To eliminate 
microbes, PMNs are equipped with a set of mechanisms to phagocytose and kill 
bacteria via reactive oxygen species (ROS), bactericidal permeability inducing 
protein, lactoferrin and degradative enzymes like elastase [47]. Once neutrophils 
fulfilled their task, they rapidly undergo apoptosis and are then eliminated via 
phagocytosis by alveolar macrophages [48, 49].  
 
Receptors and signaling pathways of the immune system 
	  
Pattern recognition receptor signaling 
The first step of the immune response is the detection of invading microbes. This 
detection system is comprised of a panel of receptors, termed pattern recognition 
receptors (PRRs), which all have the ability to recognize common structural moieties 
of microbes, also known as pathogen associated molecular patterns (PAMP) (Fig.4). 
These PAMPs are evolutionary conserved and are recognized by the innate immune 
system of many species. In contrast to the adaptive immune system, which is highly 
adaptable to conserved, as well as to new pathogenic protein structures, the innate 
immune system, recognizes these conserved structures via a repertoire of PRRs, 
which is then considered the first and immediate line of defense against infections. 
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The recognition of PAMPs is not a random process but a well-defined mechanism 
where distinct PRRs recognize distinct PAMPs, which will result in well-defined 
pathway activation.[50]. 	  
	  
Figure 4: Pattern recognition receptors, their respective pathogen-associated molecular patterns 
(PAMPs; i.e. ligand), and activated pathways [51]. 
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TLR receptor signaling 
The most important and best-characterized family of PRRs, which play a tremendous 
role in innate immunity, are TLRs. These receptors engage in the recognition of 
bacteria, their fragments or endogenous molecules, respectively (Fig.4). By now 12 
TLRs have been identified in mammals, and various TLRs recognize lipids, proteins 
or nucleic acids. TLRs are type I transmembrane proteins and are either located in 
endosomal compartments (TLRs 3, 7, 8, 9), or expressed on the cell surface (TLRs 
1, 2, 4, 5, 6) (Fig.5) [50].  
 
Figure 5: MD-2 bound to its receptor TLR4 (left: top view & right: side view) [52] 
 
Signaling downstream of TLRs unequivocally results in the activation of several 
transcription factors, most importantly nuclear factor-kB (NF-κB) (Fig.6) [53]. Since its 
discovery in 1986, NF-κB has been shown to mediate a vast variety of cellular 
response patterns while at the same time being activated by a huge number of 
stimuli. There is growing evidence that both enhanced and impaired activation of the 
NF-κB pathway may play a role during the development of human diseases. In 
resting cells, NF-κB dimers are sequestered in the cytoplasm thanks to their 
association with kB inhibitors (IkBs, e.g. IkBα, IkBβ, and others) [54]. The IkB 
proteins are composed of a central ankyrin repeat region that interacts with the 
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nuclear localizing signals of the Rel homology domain, which prevents nuclear 
translocation of NF-κB, and an N-terminal regulatory domain responsible for their 
inducible degradation. Specific (e.g. LPS, cytokines such as TNF-α or IL-1) as well as 
unspecific (e.g. γ and UV radiation, oxidative stress) activating signals can trigger the 
transduction pathways leading to the dissociation of NF-κB from IkB proteins. The 
first step of this process involves activation of the IkB kinases (IKK). The IKK 
complex consists of two catalytic subunits: IKKα (IKK1) and IKKβ (IKK2) as well as a 
regulatory subunit: NEMO (NF-κB essential modulator, IKKγ). IKKβ is crucial for IkBα 
phosphorylation triggered by such stimuli as TNF-α and IL-1. Engagement of TNF-α 
and IL-1 receptors on the cell surface lead to the activation of downstream kinases, 
which are responsible for direct phosphorylation of the IKKβ activation loop. 
Subsequently, IKKβ phosphorylates serine 32 and 36 residues in the N-terminal part 
of the IkBα protein, thus creating a binding site for the subunits of the ubiquitin ligase 
complex, which results in the rapid polyubiquitination of IkBα followed by its 
degradation in the 26S proteasome. Dissociation of IkB exposes the nuclear 
localization signal in NF-κB proteins and leads to their nuclear translocation and 
binding to the promoters of target genes [55-57]. 
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Figure 6: NFκB signaling pathway [58] 
TNF-R1 signaling 
The TNF receptor superfamily, also termed as death receptors, consists of six known 
human receptors and regulates important key roles in immune modulation via 
transcription of proinflammatory genes, cell survival, apoptosis and proliferation [59]. 
These receptors can be anchored by being type I transmembrane proteins itself, 
associated at the membrane via glycophospholipids or can even be secreted. While 
the extracellular domain is responsible for different ligand binding, the cytoplasmic 
domain is highly [60] conserved and serves as binding site for intercellular adaptor 
proteins, i.e. Fas-associated death domain (FADD) and TNF-receptor associated 
death domain (TRADD) (Fig.7) [61]. 
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Figure 7: Death Domain receptors and their respective ligand [62] 
 
While FADD is able to regulate survival or apoptosis via activation of caspase 8 and 
10, which are known to be pro-apoptotic enzymes, TRADD controls the non apoptotic 
function via recruitment of receptor-interacting protein-1 (RIP1), TNF-receptor 
associated kinase-2 (TRAF2) and cellular inhibitor of apoptosis proteins (cIAPs). 
These proteins can stimulate phosphorylation of IKK, an important trigger for 
activation of the NFκB pathway, as well as mitogen-activated protein kinases 
(MAPK), c-Jun-terminal kinase (JNK) and p38 which leads to different transcriptional 
responses necessary for modulation of cellular function and fate (Fig.8) [62]. 
Hence, while FADD and his upstream associated receptors like CD95 (Fas), DR4 
and DR5 activates mainly proapoptotic pathways, TRADD and his associated 
receptors TNF-R1 and DR3 mediate proinflammatory and immune stimulatory effects 
[63].  
Ligand binding to CD95 drives receptor clustering and binding of FADD to the 
intracellular domain of the death receptor. Binding of FADD leads to the recruitment 
and activation of caspase 8 and 10, which are initiator caspases. This complex, also 
called death-inducing signaling complex (DISC), leads to the autocatalytic activation 
of, caspase 8 and 10, which are released in the cytoplasm where they are able to 
activate their targets caspase 3, 6 and 7 by proteolytic cleavage. These caspases, 
also known as executioner caspases have various protein targets which are then 
leading to cellular apoptosis.  
As mentioned before, TRADD dependent signaling is required for TNF-R1 and DR3 
mediated responses. Similar to the formation of the DISC complex in FADD 
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dependent signaling, an intracellular complex is formed to fulfill TRADD signaling. 
Complex I is comprised of RIP-1, TRAF2 & 5, cIAP’s and the intracellular TRADD 
domain [64]. Complex I, in contrast to DISC, is able to stimulate NF-κB, JNK and p38 
downstream signaling. During formation of Complex I, cIAP’s mediates 
polyubiquitination of RIP-1. The ubiquitination process of RIP-1 can also be 
negatively regulated by A20 and caspase 8/10–associated ring protein 2 (CARP2) by 
virtue of their deubiquitinating activity [65]. Activation of RIP-1 results in the 
interaction with transforming growth factor-β-activated kinase 1 (TAK1), via TAK1 
binding proteins 1 and 2 (TAB1,2). TAK1 is furthermore able to activate NF-κB via 
interaction with the upstream IKK complex of NF-κB signaling [66]. While NF-κB 
transcriptionally activates many genes, like those encoding for proinflammatory 
cytokines and chemokines, it is also responsible for the transcription of cIAP’s and c-
FLIP’s which have mainly antiapoptotic properties. Moreover Complex I has the 
capacity to also directly activate JNK and p38 signaling pathways [67].  
An additional complex was found formed following TNF-R1 dependent signaling, and 
called complex IIA.  
After internalization of the TNF-R1 the associated proteins RIP-1 and TRAF2 
undergo conformational changes, leading to the dissociation from the TRADD 
domain. The unbound TRADD domain gains the ability to bind to FADD, which 
activates caspase 8. This complex is called IIA and drives mainly proapoptotic 
mechanisms. C-FLIP serves as a negative regulator of complex IIA (i.e. caspase 8) 
and is activated by JNK and NF-κB itself [68, 69].   
In addition, cIAP’s can inhibit the self oligomerization of deubiquitinylated RIP-1 
which would lead to TRADD binding and further caspase 8 activation. This complex 
is known as complex IIB and is negatively regulated by the IAP antagonists Smac 
and Smac mimetics, which are able to cause autoubiquitylation of cIAP and their 
further degradation by the proteasome [70]. 
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Figure 8: Signaling of FADD and TRADD dependant death receptor signaling 
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Cells involved in lung immune response 
	  
Respiratory epithelial cells 
Airway epithelial cells encounter many different airborne compounds, like viruses, 
bacteria, chemicals and hence play an important role in host defense and 
maintenance of lung homeostasis. Over the last decades, our knowledge about the 
role of airway epithelial cells has increased significantly, and extended from their 
known function as physical barriers to a complex regulatory role in host defense. 
Airway epithelial cells are able to regulate innate and adaptive immune responses by 
production of functional molecules like antimicrobial and antiviral proteins, or 
proinflammatory cytokines and chemokines. These mediators in turn activate other 
mucosal cells and contribute to the attraction of immune cells from the circulation 
[71].  
The anatomical structure of the alveolus consists of several cell types with distinct 
functions such as gas exchange, physical stability and immunological functions. 
Epithelial cells of the airway tract have a heterogeneous morphology depending on 
their allocation and function. While epithelial cells of the upper airway tract are 
ciliated (also known as ciliated epithelium) they do not serve primarily for gas 
exchange, but play a tremendous role in elevating small particles like dust, dead cells 
and mucus.  
There are two types of alveolar epithelial cells and they mediate different roles in the 
alveolus. Alveolar epithelial cells type I are covering the capillary networks 
underneath, fulfilling gas exchange, and are tightly connected to surrounding type I 
cells. Another type of alveolar epithelial cells, called type II cell, resides next to type I 
cells (Fig.9). These alveolar epithelial cells of type II have many organelles and 
lamellae corpi and secrete a thin aqueous layer, containing mainly of phospholipids 
and proteins, which is called surfactant and covers the whole alveolus. The 
surfactant layer is of extreme importance as it prevents the collapse of the alveolus 
and serves as an aqueous layer for antimicrobial peptides and immunomodulatory 
agents. As type II cells harbor many organelles, they appear bigger than type I cells. 
Type II cells can replicate locally and also replace type I epithelial cells. Another cell 
type, called Clara cells, resides in the bronchioli respiratorii and don’t generate cilia, 
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but produce short microvilli. Clara cells fulfill an important protection role, by 
secretion of a variety of products, which include Clara cell secretory protein and 
detoxifying compounds like cytochrome P450 enzymes, similar to surfactant. In 
addition they serve as progenitor cells for type II epithelial cells [72-74] 
 
Figure 9: Alveolar structure, arrows indicate gas exchange between alveolus and capillar [73] 
 
Alveolar Macrophages 
Macrophages (Mφ) are able to perform phagocytosis and are found in lymphoid as 
well as non-lymphoid tissues. In their differentiated status macrophages have distinct 
names which are determined by the location in tissues, where they are encountered. 
Macrophages are important in innate, as well as adaptive immunity and in 
maintaining homeostasis by degradation of debris [75]. Just like some DC subsets, 
macrophages originate from myeloid precursor cells in the bone marrow and are 
repopulated locally by monocytes that then differentiate to tissue macrophages. On 
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their surface macrophages express several PRRs such as TLRs, which allows these 
cells to signal the presence of pathogens [76]. 
In the lung, resident macrophages are present in alveoli and are called alveolar 
macrophages. This localization allows close contact to alveolar epithelial cells of type 
I and II, and was considered important in keeping macrophages inactive via local IL-
10 releases [77]. Binding of PAMPs to PRRs present on the surface of macrophages 
causes loss of binding to epithelial cells, which terminates the release of anti 
inflammatory cytokines. This in turn allows macrophages to release proinflammatory 
cytokines and to attract other cells of the immune system [78]. 
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Questions and Objectives 
• Has	   PVL	   the	   ability	   to	   inflame	   lung	   epithelial	   cells? 
As we could recently show that PVL is able to inflame the lung via a TLR2 
dependent activation of alveolar macrophages (Zivkovic et al. in press), we 
asked whether PVL was also able to activate epithelial cells. In addition, as 
PVL is a pore forming toxin [33], we speculated that the association with 
necrotizing pneumonia [12] could depend on PVL-induced necrosis of lung 
epithelial cells. 
 
• Is	  there	  a	  synergism	  between	  PVL	  and	  other	  virulence	  factors	  of	  S.	  aureus	  in	  
causing	  lung	  inflammation? 
S. aureus produces several toxins and virulence factors [11] and it was 
recently shown, that the presence of PVL itself is upregulating the expression 
of the virulence factor protein A [12]. Therefore we wanted to address the 
question if protein A and PVL can synergistically increase the release of 
proinflammatory cytokines by resident lung cells. 
 
• Is	  TNF-­‐R1	  playing	  an	  essential	  role	  in	  PVL	  dependent	  signaling	  and	  activation	  
of	  resident	  lung	  cells? 
Recent publications showed that protein A is able to inflame lung epithelial 
cells via a TNF-R1 dependent mechanism [79]. We suggested that the 
synergistic action of protein A and PVL could be directly, or indirectly 
dependent on TNF-R1. To address the role of TNF-R1 in vivo we created a 
chimeric mouse model using bone marrow transplantation to study the cell-
type specific role of TNF-R1 in PVL/protein A induced lung inflammation. 
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Results 
	  
PVL is able to inflame lung-epithelial cells 
It was shown by the Knapp Lab that PVL is able to inflame the lung via TLR2-
dependent activation of alveolar macrophages (Zivkovic et al. in press). Because 
TLR2 is also expressed on respiratory epithelial cells, we hypothesized that this cell 
type might also signal the presence of PVL within the lung. To study this hypothesis 
we first investigated the presence of TLR2 on MLE12 & MLE15 cells, which are 
alveolar epithelial cell lines (Fig.10). Even though the levels of TLR2 mRNA were 
low, we could find that PVL was stimulating the release of the proinflammatory 
chemokines KC, also known as CXCL-1, in vitro and by primary epithelial cells ex 
vivo (Fig.11A). Furthermore while administration of PVL to lungs of mice did not 
reveal a significant KC release in BALF, we discovered a significant increase of 
MCP-1 in lungs of PVL treated mice (Fig.11B). Because we could show earlier that 
lukF-PV is not inducing lung inflammation, it is tempting to speculate that lukS-PV 
alone is sufficient for inducing the MCP-1 release.	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Figure 10: Real- time PCR for expression levels of murine TLR2 on indicated cell types normalized to 
HPRT. 
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Figure 11: PVL is stimulating the secretion of proinflammatory chemokines (KC) by lung epithelial 
cells. (A) Immortalized murine type II lung epithelial cells (MLE15) were incubated for 16h with LukF-
PV, LukS-PV and PVL. Primary mouse airway epithelial cells of C57BL/6 mice were extracted as 
described in the materials and methods and stimulated for 16h with LukF-PV, LukS-PV and PVL. KC 
was determined by ELISA. (B) Intranasal administration of saline (CTR) or PVL to C57BL/6 mice, BAL 
and lung were removed after 6h. KC was quantified in BALF and MCP-1 in lung homogenates by 
ELISA. 
	  
PVL is not able to induce apoptosis or necrosis of lung-epithelial cells 
Because we and others could show that PVL has a potent role in lysing PMNs, we 
hypothesized that excessive necrosis during PVL-associated pneumonia might be a 
result of pore-formation on lung-epithelial cells. To address this question we 
performed several assays to investigate apoptosis and necrosis upon PVL incubation 
of respiratory epithelial cells.  
First we measured the release of lactat dehydrogenase (LDH), an enzyme which is 
located in the cytosol and only released during late apoptosis or necrosis of cells. 
The obtained data indicate that there is no elevated LDH release upon PVL 
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stimulation at prolonged incubation, i.e. murine type II epithelial cells do not die in 
response to PVL (Fig.12A). 
In a second step we analyzed DNA fragmentation upon incubation of epithelial cells 
with PVL. DNA fragmentation is a consequence of apoptosis, as genomic DNA is cut 
into small pieces by endonucleases. These small DNA pieces of apoptotic cells as 
well as the genomic DNA of intact cells can be extracted and visualized on an 
agarose gel. While the absence of apoptotic cells would results in few large bands, 
apoptotic or necrotic cells are reflected by many bands of various sizes that might 
lead to a smear. However, we could not obtain DNA fragmentation upon PVL 
stimulation whereas staurosporine treated cells displayed the typical smear of DNA-
laddering (Fig.12C). 
Finally we verified these results by using a FACS based assay using propidium 
iodide and Annexin V. Propidium iodide is binding to DNA, which can only happen 
when the cell membrane is fragmented during necrosis. During apoptosis 
phosphatidylserines flip to the outside of the cell membrane and serve as markers for 
phagocytosis. Annexin V is able to selectively bind to phosphatidylserine and both, 
propidium iodide and Annexin V can be detected using FACS. We could show that 
when treating MLE15 cells with PVL they do not undergo apoptosis or necrosis 
(Fig.12D). 
To exclude the possibility that the immortalized nature of used cell lines interferes 
with the sensitivity of cells undergoing apoptosis, we also obtained primary mouse 
airway epithelial cells and tested for apoptosis upon stimulation with PVL. In addition 
to the data obtained with MLE cells, we could show that PVL is not able to cause 
apoptosis in ex vivo primary epithelial cells by an LDH release assay (Fig.12B).  
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Figure 12: PVL is not causing apoptosis or necrosis of lung epithelial cells. (A) LDH release assay for 
PVL treated murine type II alveolar epithelial cells (MLE15) at indicated timepoints. (B) LDH release 
assay for primary mouse airway epithelial cells treated with PVL for 16h. (C) MLE15 cells treated with 
PVL for indicated timepoints and staurosporine for 16h; positive control was supplied by the kit used. 
(D) MLE15 cells were treated with PVL and Staurosporine for 16h and stained for propidium iodide & 
Annexin V and measured using FACS. 
 
PVL and Protein A together enhance the inflammatory responses in vivo 
Previous experiments could not explain tissue necrosis in the lung, because PVL 
alone is obviously not able to cause lung necrosis. Therefore we thought about 
combining PVL with other virulence factors of S. aureus, which might play a role in 
causing an overwhelming cytokine release, leading to a destructive environment 
and/or to enhance PVL’s cytotoxic effects. As mentioned above, protein A is an 
important virulence factor of S. aureus and able to inflame lungs via epithelial TNF-
R1 [79]. In addition it was reported recently, that PVL itself is upregulating the 
expression of protein A by S. aureus [12]. This led us hypothesize, that there might 
be an additive or synergistic effect of protein A and PVL. To study this idea we first 
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characterized MLE-cells and a murine alveolar macrophages cell line (MH-S) for the 
presence of TNF-R1 by FACS and RT-PCR (Fig.13). We could verify the presence of 
TNF-R1for all cell lines.  
	  
Figure 13: (A) Expression of TNF-R1 on murine alveolar macrophages (MH-S) and murine alveolar 
epithelial cells (MLE12 & 15) obtained by FACS. (B) RT-PCR for cDNA of MH-S, MLE12 & 15 cells for 
the expression of murine TNF-R1, normalized to HPRT. 
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Knowing that these cells express TNF-R1, we were able to plan further experiments 
to prove our hypothesis of synergism between protein A and PVL. To study this idea 
we investigated if protein A alone, or together with PVL might have any cytotoxic 
effect on murine alveolar epithelial cells. Testing this by LDH assay we could not find 
any evidence for cytotoxic effects of protein A and protein A / PVL on mouse alveolar 
epithelial cells (Fig.14).  
 
Figure 14: MLE15 cells stimulated with indicated substances for 24h. Primary murine alveolar 
epithelial cells stimulated for 16h. Cell death was assayed by LDH release into supernatants.  
 
  
To assay for synergistic proinflammatory effects we next stimulated MLE15 and 
primary mouse airway epithelial cells with both PVL and protein A and quantified KC 
releases (Fig.15 A & B). Indeed, the combined stimulation of cells with PVL and 
protein A resulted in an enhanced chemokine release when compared to single 
stimuli, which suggests an additive effect of both virulence factors.  
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Figure 15: PVL and protein A synergistically enhance the inflammatory response. (A) Murine alveolar 
epithelial cells (MLE15) were stimulated with PVL (0.1mg/ml), protein A (200µg/ml) or both stimuli for 
6h and chemokine concentrations were quantified by ELISA. (B) Primary mouse airway epithelial cells 
were treated with PVL, protein A or both stimuli. KC was measured in supernatants after 16h by 
ELISA. 
In an additional in vivo experiment we challenged mice intranasally with PVL and/or 
protein A, and again obtained significantly higher chemokine levels in BALF and lung 
when both stimuli were administered (Fig.16A). Counting of PMNs in BALF revealed 
in addition a significant influx of PMNs when treated with both stimuli together, as 
compared to single stimuli (Fig.16B). 
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Figure 16: PVL and protein A synergistically enhance the inflammatory response in vivo (A) Intranasal 
administration of protein A, PVL or both stimuli to mice. After 6h, mice were sacrificed and BAL was 
performed. Chemokine was measured in BALF and lungs by ELISA. (B) PMN count of BALF. 
 
TNF-R1 has an essential role in secretion of cytokines and neutrophil 
influx in vivo 
It was shown earlier that protein A has the ability to signal via TNF-R1 expressed on 
lung epithelial cells [79]. Therefore, we hypothesized that TNF-R1 might play a role in 
the synergistic effects we observed between protein A and PVL. To address this 
question, we performed an ex vivo stimulation on primary mouse airway epithelial 
cells of WT and TNF-R1 KO, to enlighten the role of TNF-R1 signaling in epithelial 
cells (Fig.17). For WT primary murine alveolar epithelial cells we could verify the 
previous finding of a synergistically increased secretion of KC when both PVL and 
protein A were provided, as compared to PVL alone. Testing primary cells derived 
from TNF-R1 KO and WT mice showed that protein A responses are reduced in KO 
cells and synergism was no longer present. However, PVL induced inflammation was 
also reduced in the absence of TNF-R1 (Fig.17). To study the in vivo role of TNF-R1 
we performed an additional in vivo experiment where we challenged WT and TNF-R1 
KO mice with protein A and/or PVL intranasally and studied the inflammatory 
response. Surprisingly the number of recruited cells was significantly reduced in 
TNF-R1 KO mice when compared to WT animals irrespective if PVL was given alone 
or together with protein A (Fig.18A). While this response is not unexpected for protein 
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A, we did not anticipate diminished cell recruitment in response to PVL alone. In 
addition, BALF analysis revealed a significant increase of MCP-1 in WT mice as 
compared to KO animals. In contrast, TNF-α levels did not differ between the mouse 
strains (Fig.18B). We therefore concluded that the efficient attraction of cells into the 
pulmonary department depended on TNF-R1, suggesting a role for TNF-α in 
secondarily boosting the inflammatory response to PVL in vivo. The fact that protein 
A administration did not result in consistently abolished inflammation in TNF-R1 KO 
mice is in agreement with previous publications, showing that protein A is not 
exclusively recognized by TNF-R1 in the lung [80]. 
 
Figure 17: TNF-R1 plays an important role in protein A / PVL dependent signaling ex vivo. Primary 
mouse airway epithelial cells were stimulated for 16h with the indicated compounds, and KC was 
quantified by ELISA.  
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Figure 18: TNF-R1 plays an important role in protein A / PVL dependent signaling in vivo. (A)WT and 
TNF-R1 KO mice were inoculated intranasally with the indicated stimuli for 6h. After this BALF was 
collected, total cells / PMNs were enumerated (B) and cytokines were measured in BALF and lung 
homogenates. 
In addition, stimulations of primary alveolar macrophages (AM) and primary 
peritoneal macrophages (PM) were performed to study the role of TNF-R1 in 
response to PVL treatment. KO macrophages showed significantly decreased levels 
of proinflammatory cytokines as compared to WT cells (Fig.19).  
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Figure 19: Murine AMs and PMs derived from WT and TNF-R1 KO mice were stimulated with PVL for 
6h and TNF-α was measured in supernatants by ELISA. 
To exclude the possibility that PVL might signal directly via TNF-R1, we stimulated 
WT and TNF-R1 KO AMs with PVL and assayed for TNF induction by RT-PCR 
(Fig.20). TNF-α stimulations were used as control. Because there was no significant 
difference in the induction of TNF-α gene expression in PVL treated WT and KO 
cells, we concluded that PVL is not signaling directly via TNF-R1. 
 
Figure 20: Alveolar macrophages of WT and TNF-R1 KO mice were extracted via BAL. The cells 
were stimulated for 1h with the respective stimuli RT-PCR was performed (TNF-α normalized to 
HPRT). 
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A bone marrow transplant experiment strengthens the importance of 
TNF-R1 in vivo and reveals an important role for lung alveolar 
macrophages 
Because previous in vivo and in vitro experiments could not clearly explain the role of 
TNF-R1 in PVL induced lung inflammation, and the contributing role of various cell 
subsets in the lung, we decided to generate chimeric mice and study the 
inflammatory response to PVL. We used 4 groups of mice, where WT recipients 
received WT or TNF-R1 KO bone marrow cells and TNF-R1 KO recipients received 
WT or TNF-R1 KO cells. This way, we anticipated to understand the respective 
contribution of TNF-R1 to lung inflammation (Table 1). 
  Group 1 Group 2 Group 3 Group 4 
Recipient Genotype WT WT TNF-R1 -/- TNF-R1 -/- 
Donor Genotype WT TNF-R1 -/- WT TNF-R1 -/- 
Table 1: The four created groups of mice according to their genotype in alveolar macrophages and 
airway epithelial cells. 
Six weeks after BMT blood was drawn and AMs were isolated to ensure 
reconstitution with donor cells (Fig.21 A & B).  
 
Figure 21: (A) PCR for TNF-R1 of whole blood DNA (25 cycles) and (B) real time PCR for TNF-R1 
normalized to HPRT of AM cDNA 6 weeks after bone marrow transplantation. 
After ensuring proper reconstitution of alveolar macrophages, mice were intranasally 
inoculated with PVL and a BAL was performed after 6h. PMN influx was enumerated 
and data clearly disclosed that TNF-R1 plays an important role in PVL-induced 
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inflammation (Fig.22A). While WT/TNF-R1 KO and TNF-R1 KO/WT chimeric mice 
showed modestly reduced PMN numbers, TNF-R1-KO/TNF-R1-KO had strongly 
reduced neutrophil counts in their lavages (Fig.22A.). Accordingly, KC as well as 
MCP-1 levels were found lowest in TNF-R1 KO/TNF-R1 KO animals (Fig.22B). 
These data illustrate that TNF-R1 on either macrophages or epithelial cells 
contributes to PVL-induced lung inflammation in vivo. Since we excluded the 
possibility that PVL signals via TNF-R1, we hypothesize that PVL induces TNF-α that 
in turn boosts the local inflammatory response via a paracrine mechanism. 
Figure 22: TNF-R1 is important for the recruitment of PMNs and the secretion of proinflammatory 
cytokines in vivo. Mice were intranasally inoculated with PVL and (A) BALF was taken enumerate 
PMN and determine (B) chemokine concentrations by ELISA.  
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Conclusion 
In this work we could show that PVL is a potent inducer of inflammatory responses 
by lung epithelial cells. Based on the earlier notion that TLR2 mediates the 
inflammatory response by AMs in response to PVL, we now show that TLR2 is 
ubiquitously expressed on mouse alveolar epithelial cells, which most likely explains 
the responsiveness of these cells.  
Epidemiologic studies link PVL to necrotizing pneumonia in humans [12, 24], which 
led us to determine the possibility that PVL might directly affect lung epithelial cells. 
Testing the effect of PVL on epithelial cell lines as well as primary murine respiratory 
epithelial cells did not enable us to show any direct toxic effect by PVL. Hence, PVL 
can only cause pores and necrosis of myeloid cells, and the clinical observation of 
lung necrosis cannot be imitated in a murine lung inflammation model.  
PVL itself has been suggested as an important virulence factor of CA-MRSA 
pneumonia, but several recent reports challenged this hypothesis, because direct 
proof of PVL’s toxic properties could not be shown in various animal models tested 
so far. Because CA-MRSA exerts more virulent traits, when compared to HA-MRSA 
strains, several groups attempted to discover potential other virulence factors. 
Among others, higher protein A expression has been shown to be associated with 
PVL-carrying bacterial strains. Knowing about the importance of protein A as an 
important virulence factor during S. aureus pneumonia [79], we hypothesized that 
PVL and protein A might synergize in inducing lung inflammation. We therefore 
studied this idea and indeed found some degree of synergism when testing epithelial 
cell lines and after infecting mice in vivo.  
When studying the role of TNF-R1, which has been reported to signal the presence 
of protein A in lungs [79], we surprisingly discovered, that the absence of TNF-R1 
significantly diminished lung inflammation in response to PVL alone. Further tests 
allowed us to illustrate that TNF-R1 is not a receptor directly signalling the presence 
of PVL. Rather, PVL is a potent inducer of TNF-α by alveolar macrophages, and 
bone marrow experiments enabled us to show that TNF-R1 present on both epithelial 
cells and macrophages mediates the inflammatory response to PVL-induced TNF-α. 
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Materials and Methods 
 
Cell culture media 
MLE media:  RPMI 1640 (Gibco) supplemented with 2% FCS and 1% 
Penicillin/ Streptomycin, additionally 2.1mg Insulin- Transferrin-.Sodium Selenite 
(Sigma), 5mg Transferrin (Sigma), 1.8mg Hydrocortisone (Sigma), 1.4mg β-Estradiol 
(Sigma) 
RAW media: RPMI 1640 (Gibco), supplemented with 10% FCS and 1% Penicillin/ 
Streptomycin; used for RAW cell line and primary alveolar 
macrophages 
BMDM media: RPMI 1640 (Gibco), supplemented with 10% FCS, 10% supernatant 
of L929 cells and 1% Penicillin/ Streptomycin 
MH-S media: RPMI 1640 (Gibco), supplemented with 10% FCS and 1% Penicillin/ 
Streptomycin and 0.01 % β-mercaptoethanol 
 
Cell lines 
MLE 12 murine type-II- lung- epithelial cells 
MLE 15 murine type-II- lung- epithelial cells 
Murine lung epithelial (MLE) cell lines with bronchiolar and alveolar origin were 
originally isolated out of lung tumors of transgenic mice, containing the viral 
oncogene simian virus 40 (SV40) large tumor antigen, under control of the human 
surfactant protein (SP-C) gene. [72]	  
Cell lines were kindly provided by Jeffrey Whitsett 
 
Chemicals and Buffers 
Annexin V Binding Buffer: 0.1 M Hepes (pH 7.4), 1.4 M NaCl, 25 mM CaCl2. Store at 
4°C 
PBS pH 7,4 10x Concentrate 
ELISA washing Buffer: 0.05% Tween 20 in PBS 
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ELISA blocking Buffer: 1%BSA in PBS 
TMB Microwell Peroxidase Substrate System 
 
Protein production and purification  
To generate PVL we used pETM11 Vectors containing LukF and LukS (Zivkovic et 
al., in press). Respective LukF-pETM11 and LukS-pETM11 constructs were 
transformed into competent DH5-α cells. BL21 (DE3) pLys competent cells 
(Invitrogen) were used for expression of pETM11 plasmids for 6h following induction 
with 0.05mM IPTG (Promega). Cells were lysed using French-Press; His-tagged 
proteins were isolated using Ni-NTA resins (Qiagen) and desalted using ZEBA 
columns (Thermo Scientific). Finally, proteins were subjected to LPS removal using 
Detoxi Gel Endotoxin Removing Columns (Thermo Scientific) until a final LPS 
concentration of <0.02 EU/ml was ensured (Charles River). 
 
LDH release assay.  
Cell death was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay 
(Promega) according to the manufacturer’s instruction. For this purpose 105/ml cells 
were incubated with indicated amounts of PVL and LDH release was determined at 
indicated times at OD450nm. 
 
Apoptotic DNA ladder assay 
2x106/ml MLE12 cells were treated with 0.1mg PVL or 1µM staurosporine (St; 
positive control [81]) for indicated time points, after which total DNA was isolated as 
suggested by the manufacturer (Roche Diagnostics). Two µg of fragmented DNA 
was run on a 1% agarose gel and visualized by ethidium-bromide staining.  
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Propidium iodide & Annexin V staining 
1x106/ml MLE12 & MLE15 cells were plated in 12 well plates and left to adhere for 4 
hours. Stimulations were done in duplicates and performed with 10µM Staurosporine 
or 0.1mg/ml PVL over 16h. Then cells were harvested in 1ml PBS/EDTA solution and 
placed in micronic tubes. Cells were washed in PBS twice and centrifuged for 5min at 
1250rpm. The resulting cell pellet was resuspended in 100µl Annexin binding buffer 
and 5µl of Annexin V and incubated for 10 minutes at room temperature. Afterwards 
4µl of a 10µg/ml propidium iodide stock solution was added, the cells were vortexed 
gently and incubated for 15 min at room temperature in the dark. The cells were 
gently vortexed and incubated for 15 min at room temperature in the dark. After 
incubation time the cells were immediately analyzed using FACS. 
	  
ELISA 
For measurement of cytokines DuoSet ELISAs (R&D) was used. 96 well flat-bottom 
high binding plates (Greiner) were coated with capture antibody (KC 2µg/ml, MCP-1 
0.2µg/ml, TNF-α 0.8µg/ml) over night. The next day, plates were washed (0.05% 
Tween 20 in PBS) and blocked (1%BSA in PBS) for 1h. The standard dilution was 
plated together with the blank in duplicates on the plate (highest standards: TNF-α 
2000pg/ml, KC 1000pg/ml, MCP-1 250pg/ml) together with the samples in their 
desired dilution and incubated for 2h. After washing the detection antibody (TNF-α & 
KC 200ng/ml, MCP-1 50ng/ml) was incubated on the plate for 2h. Following washing 
and incubation with Streptavidin HRP (1:200 dilution) for 20 minutes, the plates were 
washed and the TMB substrate mix (1:1) was added on for approx. 10-20 min. The 
color reaction was stopped with 2N sulfuric acid and the color is quantified with an 
Anthos Zenyth 340 Photometer. 
 
Real time RT-PCR 
After treatment with the stimuli according to the experimental setup, RNA was 
extracted using a RNA isolation Kit (Marchery-Nagel). After isolation of the RNA, the 
concentration of RNA was measured using the NanoDrop spectrophotometer 
(Thermo Scientific). The amount of RNA was normalized to equal amount for the 
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following reverse transcription to cDNA using the iScript cDNA synthesis kit (Biorad). 
The cDNA was used for real time PCR (Roche Diagnostics) and the obtained CT 
values were normalized to HPRT. 
 
FACS Analysis 
MH-S cells were detached with lidocain, and MLE12 /15 cells using 10mM 
EDTA/PBS solution. Harvested cells were washed twice with PBS and dissolved in 
10ml of FACS Buffer (PBS + 0.5%BSA) before counting. 5x106cells/ml were 
transferred to micronic tubes cells were stained with anti-TNF-R1 antibody (1:50; Cell 
Signaling), anti-CD14 (1:50 for MH-S & 1:10 for MLE12/15; BD Pharmingen) and 
F4/80 (1:50 MH-S only; Serotec) and left to incubate for 30 min. The cells are 
washed twice with 2ml of FACS buffer before the secondary antibody was added and 
incubated for 30 minutes in the dark to prevent degradation of the fluorophores. Cells 
were washed and subjected to FACS analysis on a FACScalibur (BD Bioscience).  
 
Isolation of primary epithelial cells from mice 
Tissue culture petri-dishes (10cm) were coated with 20µg/plate of each, anti-mouse 
CD45 and CD16/32 antibodies (ebioscience) diluted in 5ml PBS, and 96-well plates 
were coated with 200µl of 10µg/ml collagen type IV (Sigma) diluted from stock 1:100 
with 0.25% glacial acetic acid in dH2O. Both plates are covered with foil and kept 
overnight at 4°C. The vena cava of the mice was cut to drain the blood and the lung 
was flushed with saline, which was injected into the right ventricle to remove blood 
cells. After this, 3ml of dispase I (Sigma) was injected into the lung, immediately 
followed by 500µl of 1% w/v low melting agarose (Sigma). After solidification of the 
agarose the lung was extracted and kept in 1ml of dispase for 45 min at room 
temperature. Then the lung was dissected using forceps in DMEM containing 0.01% 
DNAse I (Sigma). The cell isolate was filtered through 70µm and 40µm filters, spun 
down and cells were resuspended in DMEM containing 10% heat inactivated sterile 
filtered FCS and incubated on the CD45/CD16/CD32 precoated petri dishes at 37°C 
for 2h. The supernatant of non-adherent cells was collected and the cells were 
counted using a Türck hemocytometer. Next, 5x105 cells per well were plated on the 
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collagen coated 96 well plates at 37°C in HITES medium. The next day stimulations 
were performed. 
 
Bone marrow transplantation experiments 
All animal experiments were approved by the Animal Review committee of the 
Medical University of Vienna and the Ministry of Sciences. For bone marrow 
transplant experiments we used 9 week old female C57BL/6 and TNF-R1 -/- mice. 
Four mice of each strain were used to isolate bone marrow, which was done exactly 
as described above. Recipient mice were irradiated with a dose of 9Gray, after which 
prewarmed bone marrow cell suspensions (2x106 cells in 200µl) were injected via the 
retro-orbital route. Two control mice did not receive any bone marrow cells to test for 
efficient radiation. Mice were fed autoclaved food and water and were left for at least 
6 weeks to let cells repopulate. After 6 weeks, BAL was performed and alveolar 
macrophages were tested for donor DNA (WT or TNF-R1 deficiency). Following 
verification of repopulation, mice were intranasally challenged with PVL, and the 
inflammatory response was evaluated after 6h by means of cell influx, cytokine and 
chemokine production in BALF and lung homogenates. 
 
Retro-orbital injection in mice  
(Adapted from the Institutional animal care and use committee- IACUC of the Oregon 
Health and Science University) 
The retro- orbital injection of bone marrow is an alternative way of the tail vein 
injection and requires anesthesia of the mouse. This method is being used to 
repopulate the bone marrow after removal of resident bone marrow cells by 
irradiation. The volume limit for this procedure is 200µl of cell suspension. To prevent 
clumping of cells, filter the suspension through cell strainers before injection. For 
anesthetization Isoflurane is used, further 27-30 gauge needles are needed. The 
mouse is positioned on its side, restrained by the thumb and the middle finger of the 
non- dominant hand, pulling back the loose skin over the shoulder and behind the 
ears. The index finger of the non-dominant hand is being used to draw back the skin 
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above the eye and the thumb to draw back the skin below the eye. This will result in 
slight protrusion of the eye. Insert the needle at the side of the eye through the 
conjunctiva. The tip of the needle is then positioned behind the globe of the eye in a 
cavity called “retrobulbar sinus”, where the cell suspension is being injected. The 
needle is removed gently to prevent tissue damage and injury. The eyelid is being 
closed and mild pressure is applied on the site of injection with a gauze sponge. 
During the recovery process the mouse should be monitored for adverse effects of 
the injection site as well as other behavioural abnormalities in the following days after 
transplantation. 
 
Bone marrow derived macrophages 
Mice were sacrificed by isoflurane overdose following removement of both legs at the 
hip. It is important not to injure the bone and to remove the fur carefully to prevent 
contamination of the bone marrow. The feet were cut off and the extracted bones 
were placed in ice cold PBS. In a sterile lamina flow hood the bones were sprayed 
with 70% ethanol and the flesh was removed. Femur and crus are separated at the 
knee joint. Of both, femur and crus the bone is cut on each side to reveal the 
medullary cavity. The bone marrow was flushed using a 27-30G needle filled with 
RPMI 1640 at room temperature. The cell clumps were resuspended using a 5- or 
10ml pipette. The suspension was transferred to 50ml falcons and spun down at 
1250rpm for 7 minutes at room temperature. The resulting pellet was resuspended in 
10ml of BMDM media and divided into two 10cm cell culture petri dishes (5ml per 
plate). The plates were incubated in a humidified chamber at 37°C and 5% CO2. On 
day 3 another 5ml of fresh BMDM media was added. On day 7-8 the cells were 
harvested by trypsinization or with PBS/Lidocain solution. The cells were counted 
and plated in the desired density for the experiment.   
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